Ukko

Private

Boston, MassachusettsHealthcare & Life Scienceshttps://www.ukko.us/

Last Round

Series C

Jan 8, 2026

Total Funding Raised

$92.7M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Ukko is a biotechnology company that develops immunity-boosting proteins and novel immunotherapies aimed at treating food allergies and immune-mediated conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

computational biologyprotein designfood allergy treatmenthypoallergenic ingredientsbiotechdrug discoveryallergen engineeringfood techAI drug discoverytherapeutic candidatesepitope mappingprotein engineeringimmunologyfood safetybiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ukko Comps

Public and private peers based on sector, stage, and business model.

Ukko comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ukko Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series C	Jan 8, 2026
Series B	Jan 27, 2021
Series A	Jul 24, 2017

View all Funding Rounds

Key People

Founding team and executive leadership

Anat Binur

Co-founder And CEO

Founding Team

Moshe Ben-David

Chief Technology Officer

Executive Team

Matt Ottmer

Chief Operating Officer

Executive Team

Ukko Investors

Notable investors and investment history

Ukko investors
Investor	Rounds
Fall Line Capital	Series C, Series B
Israel Biotech Fund	Series C
Skyviews Life Science	Series B
TIME Ventures	Series B
Khosla Ventures	Series C, Series A, Series B
Innovation Endeavors	Series A, Series B
Time Ventures	Series B

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 17, 2026
Monthly visitors grew 108% MoM, reaching 2.5K.

View all signals

Ukko Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Ukko Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ukko's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts

Employee Range58

Year Founded2016

Last FundingJan 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.